var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('4/10 - 7:30 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
4/7 - 1:15 PM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | \n'); } if (allow) { document.write('
3/20 - 7:30 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
3/5 - 11:54 PM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Announces Pricing of Public Offering of Common Stock | \n'); } if (allow) { document.write('
3/4 - 4:18 PM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Announces Proposed Public Offering of Common Stock | \n'); } if (allow) { document.write('
3/4 - 2:30 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM | \n'); } if (allow) { document.write('
2/22 - 7:30 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update | \n'); } if (allow) { document.write('
2/7 - 7:35 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan | \n'); } if (allow) { document.write('
2/6 - 7:30 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
2/5 - 7:30 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | \n'); } if (allow) { document.write('
2/2 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months | \n'); } if (allow) { document.write('
1/30 - 7:01 AM \; \; | \n'); } if (allow) { document.write('Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics | \n'); } if (allow) { document.write('
1/18 - 7:00 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines | \n'); } if (allow) { document.write('
1/10 - 5:16 PM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine | \n'); } if (allow) { document.write('
1/10 - 7:30 AM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | \n'); } if (allow) { document.write('
1/3 - 4:30 PM \; \; | \n'); } if (allow) { document.write('BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference | \n'); } if (allow) { document.write('
1/3 - 7:30 AM \; \; | \n'); } if (allow) { document.write('BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON) | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write(' |